Lowest Price Guaranteed
Pages
217
Last Updated
July 2026
View Count
23089
The global CRISPR based therapeutics market, valued at USD 0.1 billion in 2025, is projected to reach USD 0.2 billion in 2026 and USD 6.3 billion by 2035, with a CAGR of 43.8% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
CRISPR is a genome editing technology that allows scientists to make targeted changes in DNA. In simple terms, it works like a precise editing tool that can find a specific part of the genetic code and modify it. This makes CRISPR different from many traditional treatments, which usually manage disease symptoms rather than addressing the underlying genetic cause.
The CRISPR domain has evolved from basic scientific research into an important area of advanced therapeutics. Initially, CRISPR was studied as a natural defense system found in bacteria. However, over time, scientists adapted this system into a powerful tool for editing genes. This opened the door for new treatment approaches, especially for diseases caused by faulty genes or abnormal cell behavior. As research progressed, CRISPR moved from laboratory experiments into clinical development and, more recently, into approved therapies.
CRISPR based therapeutics came into focus because many genetic diseases, cancers, and rare disorders still have limited treatment options. In several cases, existing therapies only control symptoms or require lifelong treatment. CRISPR has the potential to offer a more durable treatment approach by targeting the root cause of disease. It is being used mainly in blood disorders such as sickle cell disease and beta-thalassemia, and is also being explored for cancer, autoimmune diseases, rare genetic disorders, cardiovascular diseases, and infectious diseases.
CRISPR Therapeutics has played an important role in advancing the market. The company, along with Vertex Pharmaceuticals, developed CASGEVY, which became the first approved CRISPR based therapy. This marked a major milestone for the industry and showed that CRISPR can move beyond research into real clinical use. The company is also working across multiple areas such as blood disorders, oncology, autoimmune diseases, cardiovascular diseases, regenerative medicine, and rare diseases, reflecting the wider growth potential of the CRISPR therapeutics market.
Overall, the CRISPR based therapeutics market is moving from an emerging scientific concept to a practical treatment area. This technology is gaining traction as it can address diseases at their genetic source and may reduce the need for repeated or lifelong treatments. While challenges such as delivery, safety, cost, and scalability remain, CRISPR is expected to become an important part of the future treatment landscape for genetic diseases and other complex disorders.
| Company | Headquarters | Name of Drugs | Core Technology | Key Therapeutic Focus |
| Vertex Pharmaceuticals / CRISPR Therapeutics | US / Switzerland | CASGEVY | Ex vivo CRISPR/Cas9-edited autologous HSC therapy | Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia |
| CRISPR Therapeutics | Zug, Switzerland / Boston, US | CTX310, CTX320 / CTX321, zugo-cel, CTX460, CTX340 | CRISPR/Cas9, SyNTase, LNP delivery, allogeneic CAR-T | Cardiovascular, Autoimmune, Oncology, Rare Diseases |
| Intellia Therapeutics | Cambridge, MA, US | Lonvo-z, nex-z, REGV131-LNP1265 | In vivo CRISPR/Cas9, LNP delivery, targeted insertion | HAE, ATTR Amyloidosis, Hemophilia B |
| Beam Therapeutics | Cambridge, MA, US | BEAM-302, BEAM-301 | Base editing, in vivo LNP | AATD, Glycogen Storage Disease Ia |
| Eli Lilly / Verve Therapeutics | Indianapolis, IN / formerly Boston, MA | VERVE-102, VERVE-201, VERVE-301 | In vivo base editing, GalNAc-LNP | ASCVD, Familial Hypercholesterolemia, Dyslipidemia |
| Prime Medicine | Cambridge, MA, US | PM359, Wilson disease, AATD, cystic fibrosis programs | Prime editing, ex vivo and in vivo approaches | CGD, Liver, Lung, Immunology / Oncology |
| Caribou Biosciences | Berkeley, CA, US | CB-010, CB-011 | CRISPR-edited allogeneic CAR-T | B-cell NHL, Multiple Myeloma |
| Editas Medicine | Cambridge, MA, US | EDIT-401 | In vivo CRISPR gene editing, LDLR upregulation | Hyperlipidemia, ASCVD |
Based on research, we have segmented the CRISPR based therapeutics market into type of therapy, therapeutic approach, target therapeutic area and geographical regions.
By Type of Therapy
By Therapeutic Approach
By Target Therapeutic Area
By Geographical Regions
In March 2026, CRISPR Therapeutics raised approximately $585 million through an upsized offering of convertible senior notes. This funding is primarily intended to support the advancement of its gene-editing therapy pipeline, including ongoing clinical programs for cardiovascular diseases, oncology, autoimmune conditions, and further development of its CASGEVY collaboration.
Fueled by demand for precision gene-editing therapies and rapid improvements in delivery platforms such as lipid nanoparticles, optimized viral vectors, and emerging non-viral carriers, the CRISPR based therapeutics market is poised to grow significantly in the near future.
Eric Kmiec (Executive Director and Chief Scientific Officer, CorriXR Therapeutics), stated that, "Sickle cell disease was always a popular target, and Stuart Orkin's work on understanding the globin locus and discovering that there was a repressor of foetal globin expression led to the evolution of what we see today with the approval of CASGEVY."
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:
This segment highlights the distribution by value for the CRISPR based therapeutics market across various types of therapies, such as HSC therapies, CAR-T Cell therapies, T-cell therapies and TIL therapies.
Currently, hematopoietic stem cell (HSC) therapies hold the largest share of the CRISPR based therapeutics market owing to their advanced stage of clinical development and their strong potential to provide durable, one-time treatments for genetic blood disorders. HSCs can be harvested and then reinfused into patients in order to restore normal blood cell function, making them an ideal platform for treating inherited hematological diseases. Furthermore, the expanding pipeline of HSC-based CRISPR therapeutics and continued advancements in gene-editing technologies have reinforced the segment's dominant position in the market.
Further, the tumor-infiltrating lymphocyte (TIL) therapies are expected to grow at a significant pace during the forecast period due to increasing efforts to combine CRISPR gene editing with adoptive cell therapy to improve anti-tumor efficacy. CRISPR technology enables precise genetic modifications of TILs, such as disrupting immune checkpoint genes or enhancing tumor-targeting capabilities, thereby improving their persistence and therapeutic activity within the tumor microenvironment.
The approval of Amtagvi, the first FDA-approved TIL therapy for advanced melanoma, has renewed interest in this treatment modality and encouraged the development of next-generation CRISPR-engineered TIL products. In addition, the growing incidence of solid tumors, increasing investment in personalized cancer immunotherapies, and expanding clinical pipelines evaluating gene-edited TIL therapies are expected to drive significant growth of this segment during the forecast period.
This segment highlights the distribution by value for the CRISPR based therapeutics market across various therapeutic approaches, such as ex vivo therapies and in vivo therapies.
Currently, the ex vivo therapies hold the largest share of the CRISPR based therapeutics market owing to their greater clinical maturity, controlled gene-editing environment, and established regulatory pathway. In such approaches, patient-derived cells are genetically modified outside the body, allowing precise editing, rigorous quality control, and verification of editing efficiency before reinfusion into the patient. This minimizes the risk of unintended off-target effects and enhances treatment safety.
Notably, the in vivo therapies segment is expected to grow at a significant pace during the forecast period due to rapid advancements in targeted gene-editing delivery technologies and the potential to directly treat diseases within the patient's body without the need for cell extraction or transplantation. These therapies can simplify treatment procedures, expand access to a broader patient population, and enable the treatment of disorders affecting organs such as the liver, eye, muscle, and central nervous system. A notable example is KJ-003 and the clinical advancement of in vivo CRISPR candidates such as VERVE-102, which utilizes lipid nanoparticles to deliver gene-editing components for the treatment of cardiovascular disease.
This segment highlights the distribution by value for the CRISPR based therapeutics market across various target therapeutic areas, namely hematological disorders, oncological disorders, genetic disorders, ophthalmic disorders, infectious diseases and other disorders.
Currently, hematological disorders hold the largest share of the CRISPR based therapeutics market owing to the advanced clinical maturity of gene-editing approaches for inherited blood diseases and the accessibility of hematopoietic stem cells for ex vivo editing. Disorders such as sickle cell disease (SCD), transfusion-dependent β-thalassemia (TDT), and certain inherited immunodeficiencies are caused by well-characterized single-gene mutations, making them ideal candidates for CRISPR-mediated genome editing. Additionally, the strong pipeline of CRISPR-edited hematopoietic stem cell therapies, favorable clinical outcomes, and increasing adoption of precision medicine have reinforced the dominant position of the hematological disorders segment in the CRISPR based therapeutics market.
The genetic disorders segment is expected to grow at a significant pace during the forecast period due to rapid advancements in in vivo gene-editing technologies and expanding applications of CRISPR beyond hematological diseases. Researchers and biotechnology companies are increasingly developing CRISPR based therapies for inherited disorders affecting the liver, eye, muscle, and central nervous system, where conventional treatment options remain limited. For example, Verve Therapeutics is advancing VERVE-102, an in vivo CRISPR based therapy for familial hypercholesterolemia, while Intellia Therapeutics has reported encouraging clinical data for NTLA-2002, a CRISPR therapy targeting hereditary angioedema.
According to our projections, North America is likely to capture the majority of the CRISPR based therapeutics market share in the current year. This is due to its well-established biotechnology ecosystem, strong clinical research infrastructure, and substantial investments in gene-editing technologies. The region is a hub to several pioneering CRISPR companies, including CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, and Verve Therapeutics, which are actively advancing clinical programs across hematological, cardiovascular, and genetic disorders. In addition, North America benefits from strong government and private funding, favorable regulatory support, and a high concentration of leading academic institutions and clinical trial centers. This helps reinforce North America's dominant position in the market.
The market in Asia-Pacific is likely to grow at the highest CAGR during the forecast period. This is due to increasing investments in biotechnology research, expanding genomic medicine initiatives, and rising government support for advanced therapeutic development. Countries such as China, Japan, South Korea, and India are strengthening their capabilities in gene-editing research through strategic funding, expanding clinical trial activity, and collaborations between academia and industry.
For example, China has rapidly expanded its CRISPR research landscape, with companies such as EdiGene advancing CRISPR-edited cell therapies and hematopoietic stem cell therapies into clinical development, while Japan continues to invest in regenerative medicine and genome-editing research through supportive regulatory frameworks. Furthermore, the growing prevalence of genetic disorders and cancer, improving healthcare infrastructure, increasing availability of precision medicine, and rising investments by regional biotechnology companies are expected to drive robust growth of the Asia-Pacific CRISPR based therapeutics market during the forecast period.
| Key Report Attribute | Details | |
| Historical Trend | Since 2021 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $ 0.2 Billion | |
| Market Size 2035 | $ 6.3 Billion | |
| CAGR (Till 2035) | 43.8% | |
| Segments Covered |
|
|
| Key Players |
(A complete list of players captured is available in the report) |
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |